The Development Bank of Wales backed the fintech startup to accelerate its technology capabilities and create new jobs.
"Mobile wallets such as Apple Pay are growing in adoption but research shows that persoanlisation is a critical in the success of digital marketing. While customers want compelling content and a personalised experience, payment and financial apps are not currently meeting consumer expectation."
The equity investment follows an introduction by business angel Craig Gulliford.
"People want to gain more insight into their own health in order to reach their personal best. Our results dashboard is intuitive and easy to understand so that we can empower the consumer to understand more about their own body. Results of the at-home tests are processed within 48 hours via a personalised dashboard and I am proud to say that we are the only biomarker profiling company to offer our customer a mobile app."
The financing round was led by Beringea with participation from new and existing investors.
"Our goal as Second Nature is to solve obesity. We need to rise above the confusing health misinformation to provide clarity about what’s really important: changing habits. Our new brand and investment will help us realise that,"
LDC acquired a minority stake in the software reseller as previous backer BGF exited the business.
"We are experiencing growing demand for our services from a large, expanding customer base, many of whom have been with us for over 20 years. With the support of BGF over the last three years, we have been able to significantly grow our existing activities and acquire complementary businesses that are now core to the Solid Solutions family."
The funding round was led by UK Innovation & Science Seed Fund with participation from LifeArc and Parkwalk.
"The increasing incidence of debilitating ophthalmic diseases brings morbidity and economic cost, and we are pleased to announce our seed funding today to tackle these urgent issues. We thank our investors UKI2S, LifeArc and Parkwalk for their support, and look forward to working with them to build Ikarovec into a leading gene therapy company."